Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Valneva
ISIN FR0004056851
|WKN A0MVJZ
Market cap (in EUR)
653 m
Country
France
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals France
Financials
Key metrics
| Market capitalisation, EUR | 653 m |
| EPS, EUR | -0.61 |
| P/B ratio | 4.3 |
| P/E ratio | 134.6 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 170 m |
| Net income, EUR | -12 m |
| Profit margin | -7.22% |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.